Mercy BioAnalytics: Funding, Investors & Team (Sep 2026)
The objective of Mercy BioAnalytics, a biotech enterprise established in Natick, Massachusetts in 2018 by Paul Blavin and Joseph Sedlak, is to enhance and preserve human lives by detecting cancer at an early stage. They have created a technique which utilizes extracellular vesicles (EVs), small cell-derived nanoparticles present in large numbers in blood that contain important information about their parent cell, to diagnose stage I cancer.
Mercy BioAnalytics has raised $41.0M across 1 funding round on record, the most recent a Series A of $41.0M announced in Apr 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mercy BioAnalytics Company Profile and Key Stats
Latest funding round on record: Apr 2023.
Mercy BioAnalytics Funding Rounds
Mercy BioAnalytics Founders and Leadership Team
Contact details for the Mercy BioAnalytics team: 1 of 1 has an email address on file.
Start 14-day free trial →Mercy BioAnalytics Funding Compared to Other Biotechnology Startups
Mercy BioAnalytics' latest round of $41.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mercy BioAnalytics in Biotechnology and Natick
Companies Similar to Mercy BioAnalytics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Mercy BioAnalytics Funding FAQs
What does Mercy BioAnalytics do?
The objective of Mercy BioAnalytics, a biotech enterprise established in Natick, Massachusetts in 2018 by Paul Blavin and Joseph Sedlak, is to enhance and preserve human lives by detecting cancer at an early stage. They have created a technique which utilizes extracellular vesicles (EVs), small cell-derived nanoparticles present in large numbers in blood that contain important information about their parent cell, to diagnose stage I cancer.
How much funding has Mercy BioAnalytics raised?
Mercy BioAnalytics has raised $41.0M across 1 round on record. The most recent is a Series A of $41.0M announced in Apr 2023.
When did Mercy BioAnalytics last raise funding?
Mercy BioAnalytics' most recent funding round on record is a Series A of $41.0M, announced in Apr 2023.
Who is the CEO of Mercy BioAnalytics?
Dawn Mattoon is listed as CEO at Mercy BioAnalytics.
Where is Mercy BioAnalytics headquartered?
Mercy BioAnalytics is based in Natick, Massachusetts, United States.
How many employees does Mercy BioAnalytics have?
Mercy BioAnalytics is in the 11-50 employee band.
How does Mercy BioAnalytics' funding compare to other Biotechnology startups?
Mercy BioAnalytics' latest round of $41.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Mercy BioAnalytics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mercy BioAnalytics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.